The Federal Trade Commission has reached a settlement with Surescripts that would prohibit the prescription-technology company from engaging in exclusionary conduct and enforcing noncompete agreements.

The FTC on Thursday proposed an order in federal district court that would resolve the agency’s claim that Surescripts used anticompetitive tactics in an unlawful effort to monopolize the e-prescription drug market illegally.